Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United Kingdom
/
Pharmaceuticals & Biotech
Create a narrative
AstraZeneca Community
LSE:AZN Community
1
Narratives
written by author
0
Comments
on narratives written by author
171
Fair Values set
on narratives written by author
Create a narrative
AstraZeneca
Popular
Undervalued
Overvalued
Community Investing Ideas
AstraZeneca
AN
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
Phase III Data For New Medicines Will Strengthen Future Outlook
Key Takeaways Expansion in emerging markets and ongoing pipeline development could significantly drive future revenue growth. Investment in next-generation capabilities and a catalyst-rich period ahead may bolster long-term revenue and profitability.
View narrative
UK£135.15
FV
23.3% undervalued
intrinsic discount
6.04%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
123
users have followed this narrative
Updated
narrative
Your Valuation for
AZN
AZN
AstraZeneca
Your Fair Value
UK£
Current Price
UK£103.62
46.5% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
71b
2015
2018
2021
2024
2025
2027
2030
Revenue US$70.6b
Earnings US$9.2b
Advanced
Set Fair Value